Fetal microchimerism in mouse caerulein-induced pancreatitis model

Zahra Vojdani 1*, Jafar Bagheri 1, Tahereh Talaei-Khozani 1, Negar Azarpia 2, Mahin Salmannjad 1, Ali Farrokhi 3
1 Laboratory for Stem Cell Research, Anatomy Department, Medical School Shiraz University of Medical Sciences, Shiraz, Iran
2 Transplantation Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 Royan Institute for Stem Cell Biology and Technology, ACECR Department of Stem Cell and Developmental Biology, Cell Science Research Center, Tehran, Iran

ABSTRACT

Objective(s): Fetal microchimerism is the persistence of allogeneic cell population that transfer from the fetus to the mother. The aim of this study was to evaluate the presence of fetal microchimerism in the pancreas of the mouse with acute pancreatitis (AP).

Materials and Methods: In this experimental study, female wild-type mice were mated with male EGFP+. AP model was obtained by injection of caerulein two days after delivery. Sixty mice were divided into 3 groups: the virgin pancreatitis-induced animals, pregnant pancreatitis-induced animals mated with transgenic EGFP mice, and pregnant sham animals. To prove pancreatitis induction, the blood amylase and lipase were assessed; and pancreas was removed from a subpopulation of each group for histopathological examinations after 6 hr. The remaining mice were kept for 3 weeks and histopathological examination, immunohistochemistry, and PCR were performed.

Results: EGFP+ cells were found in acini and around the blood vessels in the pancreas of pregnant pancreatitis-induced animals. They differentiated to acinar, adipocyte-like, and mesenchymal-like cells. PCR showed that 20% of the pregnant pancreatitis-induced animals were EGFP+.

Conclusion: It seems that pregnancy has a beneficial impact on caerulein-induced pancreatitis and improves the pancreatitis score in mice.

Introduction

Microchimerism is defined as the long-term persistence of a population of allogeneic cells (or DNA) (1) within an individual (2). Microchimerism happens as a result of the reciprocal trafficking of the cells between the fetus and mother during pregnancy, transfusion between twins, organ transplantation, and blood transfusion (3, 4). Microchimerism may have a physiological role in tissue repair, is associated with autoimmune diseases (5), or is involved in some cancers (3).

Most of the microchimerism was observed during pregnancy (4). Microchimerism can be divided into two types: the cells that are transferred from the fetus to mother, called fetal microchimerism cells (FMC), and the cells that are transferred from the mother to fetus, called maternal microchimerism cells. Both of these cells can remain in the blood and tissues for decades or even the whole life (6).

In humans, FMC is the most common form of microchimerism. Although FMC has been reported to happen even before the formation of the placenta (7), it has been detected to be a result of passing the fetal cells through the placenta (8) at four to six (9) and seven weeks of gestation. FMC has been derived from hematopoietic stem cells (10), hematopoietic cell lineages including B and T lymphocytes, monocytes, natural killer cells, CD34+ (11), CD38+ (12), macrophages and granulocytes (1), red blood cells, or mesenchymal stem cells (13). They also have been derived from the trophoblast cells, primitive endoderm, and epiblast. The cells enter the maternal circulation and transport to the bone marrow, proliferate in the body, remain in the mother's body for decades (14,15), and differentiate into several cell types (16). In maternal tissues, these cells have been traced as neurons and neuroglia (11), hepatocytes, kidney's tubular epithelium (17), cardiomyocytes (18), intestinal epithelium, endothelial cells (10), and thyrocytes (11) as well as in organs such as the lung (13), skin, spleen, adrenal gland (18), appendix (19), and spinal cord (20).

Various hypotheses suggest the roles and functions of FMC in the mother's body. FMC may trigger graft versus host reaction that leads to autoimmune diseases (11). FMC has been suggested to be involved in autoimmune diseases such as scleroderma, primary biliary cirrhosis, systemic lupus erythematosus, myositis, Sjogren's syndrome (21), rheumatoid arthritis (22, 23), type I diabetes (24), Hashimoto's thyroiditis, Grave’s disease (9), and multiple sclerosis (6). Long-term presence of FMC in the mother's body increases the capability of...
the maternal immune system to respond to FMC and this may lead to various immunologic diseases in the mothers (12).

Other evidence suggests that exchanging cells in both types of microchimerism have a role in triggering non-autoimmune diseases, such as cancer in the thyroid, cervix, lung, breast, colon, uterus, ovary, and also in melanoma and hepatitis C (26).

It has been also hypothesized that FMC is distributed in maternal tissues following injury, acquires stemness activities, and participates in tissue repair. After delivery, these cells are suggested to be placed in the maternal stem cells niche (12). These cells differentiate and start regenerative responses in damaged maternal tissues (10, 27). FMC has been shown to differentiate into hepatocytes and renal tubular cells in the maternal liver and kidney, and is also involved in tissue repair (17). The presence of fetal cells in the maternal heart was also reported after cardiomyocyte inflammation. FMCs were shown to migrate to the myocardium and differentiate into cardiomyocytes (18). FMC migration to the lung and bone marrow has been detected also in mouse (13). Interestingly, the fetal cells have been shown to pass through the blood-brain barrier and, acquire different morphology in response to brain injury (31), depending on the position. Fetal cells also differentiate into neurons, astrocytes or oligodendrocytes in the spinal cord (20).

Acute and chronic pancreatitis are common gastrointestinal disorders that are very important in terms of reducing the quality of life for patients. Acute pancreatitis causes inappropriate activation of pancreatic zymogen (including trypsinogen) and increases lysosomal enzymes (including cathepsin) in the pancreas, which leads to cell death and necrosis of the pancreatic cells. It also causes extensive inflammatory response and release of inflammatory mediators such as TNF-α, IL-1, IL-6, and neutrophil infiltration in the pancreas (29, 30). In acute pancreatitis, mitochondria are disabled, increasing the number and size of autophagy vesicles.

The development of pancreatitis animal models has increased our understanding of pathogenesis and pathophysiology. They include models consisting of secretagogue hyperstimulation (caerulein injection), ethanol feeding, bile salt duct infusion, choline-deficient ethionine-supplemented, basic amino acid, specific cytokines injection, and infection due to coxsackie virus group B (31).

The aim of this study was to investigate the presence of FMCs in the pancreatic tissues of mice afflicted with acute pancreatitis. This study for the first time shows the positive effects of pregnancy in acute pancreatitis.

Materials and Methods

Animals

This work was an interventional experimental study. All animals were handled according to the guidelines approved by ethics committee of Shiraz University of Medical Sciences. Transgenic EGFP adult male mice (NMRI strain), weighing 25–30 g (Royan Institute) and wildtype female virgin mice weighing 25–30 g (purchased from the animal lab of Shiraz University of Medical Sciences) were selected randomly. Animals were kept in standard conditions (12 hr light/dark period, temperature of 18–22 °C) with free access to food and water.

Study design

Sixty mice were divided into three groups. The first group consisted of virgin pancreatitis-induced animals and received caerulein (Sigma, Germany). The second group consisted of pregnant sham animals mated with transgenic GFP mice, and two days after delivery, they received the vehicle (normal saline). The third group consisted of pregnant pancreatitis-induced animals mated with transgenic GFP mice, and two days after delivery, they received caerulein. Each group was divided into two subgroups; the first subgroups were killed 6 hr after the last injection and the second subgroups were kept under the standard conditions for 3 weeks.

Induction of acute pancreatitis

To find the appropriate dose of the caerulein in mice, we designated a pilot study based on the protocol introduced by Lerch and Gorelick, and Warzecha et al. in a rodent model (31, 32). To do this, 50, 60, and 80 μg/kg caerulein were injected IP in two mouse strains bulb/c and NMRI. The mice were killed after 6 hr and serological and histological tests were performed. The best dose was chosen to induce pancreatitis in mice.

According to the aforementioned pilot, acute pancreatitis was induced in a mouse model by intraperitoneal injection of 80 μg/kg caerulein, 5 injections at an interval of 1 hr. To confirm the pancreatitis induction, blood samples were taken from the mice 6 hr after the last injection. The mice were killed after 6 hr or 3 weeks; their pancreata were removed, fixed in 10% formalin, sectioned at 5 μm thicknesses, and stained with H&E. The sections were examined under a light microscope (BX41, Olympus, Tokyo, Japan) and a scoring system grade form 0–3 (29) was used to evaluate the severity of pancreatitis.

Leukocyte infiltration (acute and chronic), interstitial edema, vacuolization and gland destruction of pancreatic acinar cells were considered as major criteria in the scoring system. Total white blood cell (WBC) count was evaluated by examining three randomly selected 1 mm² areas of the exocrine pancreas and averaging the scores. The definition of acute and chronic inflammation was also obtained from the same areas based on neutrophil and macrophage/plasma cell counts. The morphological criteria in the scoring system, 0–3, were as follows in all groups: the “0” score means the absence of any histologic finding, score “1” means there is mild inflammation, score “2” means there is moderate inflammation, while score “3” means there is severe inflammation in the pancreas.

Criteria were defined for scoring levels (0 = absent, 1 = mild, 2 = moderate, 3 = severe) for other lexicon components also obtained on three randomly selected 1 mm² areas of the exocrine pancreas and averaging the scores.

Amylase and lipase activity assay

The heart blood samples were collected 6 hr after the last injection and centrifuged at 3000 RPM for 10 min;
then, the sera were collected for biochemical analysis. Amylase and lipase activity were assessed using an amylase kit (Mancompany, Iran) and a lipase DC kit (Pars Azmun, Iran) according to the manufacturers’ instructions.

Immunohistochemistry

Immunohistochemistry analysis of the pancreatic tissue sections was performed using an anti-GFP antibody (Abcam, England). In brief, the pancreas sections at 5 µm thickness were mounted on propylamine-coated slides. The tissue sections were then deparaffinized, and endogenous peroxidase activity was blocked by incubation in 3% H2O2 in methanol for 10 min(31). For antigen retrieval, the sections were heated in citrate buffer (pH 6.0) (33) at 96 °C for 15 min. Non-specific binding sites were blocked by incubating the sections in PBS containing 10% goat serum for 60 min. The slides were then incubated overnight with primary anti-GFP (Abcam, England) antibody diluted at 1:1000. The slides were gently washed with PBS three times for 5 min and incubated with streptavidin-HRP (Abcam, England) diluted at 1:10000 for 30 min. The slides were washed with PBS twice for 5 min and then incubated with diaminobenzidine chromogen (Sigma, Germany) for 5 min. Finally, the slides were counterstained using hematoxylin for 6 sec, dehydrated in xylene, and mounted.

Polymerase chain reaction

To confirm the presence of FMC, the presence of EGFP genes in the mice mothers, who mated with EGFP transgenic mice, was detected by PCR. DNA was extracted from the pancreas of each animal using a DNA extraction kit (GeNet Bio, Korea) according to the manufacturer’s instructions. DNA concentrations were detected by nanodrop spectrophotometry at 280/260 nm wavelength. Primers were designed by NCBI-Pick primer and primer3 and then analyzed by Allele ID and NCBI-Blast. The sequences of the primers are shown in Table 1. DNA was added to 10X PCR buffer containing 25 mM MgCl2, 5 unit/µl taq DNA polymerase and 10 mM dNTPs. The initial denaturation time was 10 min at 94 °C with annealing temperatures at 94 °C for 30 sec, 59 °C for 45 sec, and 72 °C for 45 sec. The final extension step was at 72 °C for 10 min. The number of the cycles was 38 times; PCR products were run on agar gel.

Statistical analysis

The mean values of the serum concentrations of amylase and lipase were compared using ANOVA and LSD tests. The data were expressed as mean ± SD. The median value of the pathological score was compared using Kruskal-Wallis and Mann-Whitney tests. The data were expressed as median range. A P-value less than 0.05 was considered as significant difference. The statistical analyses were performed using SPSS 15.0 for Windows (IBM, USA).

Results

Serological findings

The data from a pilot study in both mouse strains showed that the best dose for pancreatitis induction was 80 µg/kg. However, the balb/C mouse can be considered a superior animal model to the NMRI strain as indicated by the serological tests (Figure 1). The serological tests showed that injection of 80 µg/kg caerulein-induced higher amylase and lipase activities in balb/C than in NMRI mice.

Pathological finding

The histopathological data showed the symptoms of pancreatitis in caerulein-induced animals. These symptoms
included leukocyte infiltration into the exocrine part of the pancreas, vacuolization of acinar cells, gland destruction, and edema (Figure 3). The amount of connective tissue showed an increase in pregnant caerulein-induced pancreatitis.

Six hr after the last caerulein injection, the median value of the scoring for acute inflammation was "2"; for chronic inflammation it was "1" and for vacuolization it was "2" for non-pregnant and "1" for pregnant pancreatitis induced animals. In pregnant sham animals, no pancreatitis symptom was observed.

After 3 weeks, the median value of the scores for acute inflammation was "2" for non-pregnant pancreatitis induced animals. Pregnancy significantly decreased the median value of acute inflammation score to "1" in pregnant pancreatitis animals. Pregnancy led to a significant decrease in the median value of chronic inflammation score from "3" in non-pregnant to "2" in pregnant pancreatitis animals. The scoring value for gland destruction criterion showed a significant reduction from "2" for non-pregnant to "1" in pregnant pancreatitis animals (Figure 4).

**Immunohistochemistry findings**

Immunohistochemistry showed the presence of the EGFP* cells in a limited location of the pancreas in some pregnant animals. The EGFP* cells were involved in the formation of acinar cells in pregnant caerulein-induced pancreatitis (Figure 5). Also, some EGFP* cells were found within the connective tissue near the blood vessels, containing inflammatory leukocytes. The cell morphology indicated the existence of some adipocyte-like cells with one or more lacuna and mesenchymal-like...
cells with a centrally located nucleus and a few processes in pregnant caerulein-induced animals (Figure 6). In sham animals, a few EGFP+ cells were also found within pancreatic acinar cells of some samples. The number of EGFP+ cells was much less than those found in pregnant caerulein-induced pancreatitis.

PCR finding
PCR assay confirmed the immunohistochemistry and showed the presence of the EGFP gene in the DNA extracted from 20% of the pregnant caerulein-induced animals. In virgin pancreatitis-induced and pregnant sham animals, no band for EGFP was formed. The EGFP-positive animals were used as positive controls (Figure 7).

Discussion
This study revealed that pregnancy significantly reduced the score of the induced pancreatitis, and the presence of EGFP-positive cells indicated that the microchimerism transfer from embryo to the mother may result in the regeneration of the exocrine part of the pancreas. Fetal cells have been shown to cross the placental barrier and enter the blood circulation, and then they are implanted in various tissues (17). It has been reported that fetal cell numbers increase in multiparous mothers (20). Pathological changes in the mother’s tissues caused an increase in the number of the fetal cells in the blood and peripheral tissues, and higher numbers of fetal microchimerism have been reported in the chronic state of the injured tissues (17).

Fetal microchimerisms were detected in both normal and injured tissues after pregnancy. The presence of these cells was detected in the normal spinal cord. The cells have been shown to differentiate into neurons as well (20). Human fetal microchimerism has also been shown to differentiate into cardiomyocytes (18). The presence of fetal microchimerism was demonstrated in the pancreas, liver, bone marrow and kidney after diabetes induction. It has been suggested that some multipotent fetal cells migrate into the mouse maternal tissues and differentiate into pancreatic acinar cells, hepatocytes and epithelial tubular cells (27). Besides, ethanol-induced hepatotoxicity and gentamycin-induced nephrotoxicity in mice mothers led to the presence of GFP-positive hepatocytes and epithelial tubular cells originating from the fetuses (17). The results of the current study also confirmed the presence of a few EGFP+ cells in IUI sections of pregnant sham pancreas; however, the number was too limited to detect by PCR. Immunostaining showed that the acinar cells originated from the fetal-derived cells in the pregnant sham and both acinar cells and adipocytes-like cells in the pregnant caerulein-induced animals. The results also showed that the microchimeric cell fate changed by induction of pancreatitis. Increase in FMC number in pregnant caerulein-induced animals may be attributable to FMC proliferation after injury induction.

The PCR data showed that just 20% of the mice contained the EGFP gene after the first pregnancy. This result was the same as the work performed elsewhere on the spinal cord; however, they found an increase in the frequency of GFP-positive cells in multiparous mice (20).

There is a controversy about the role of fetal microchimerism in the occurrence of diseases. In diseases such as scleroderma and primary biliary cirrhosis, the presence of fetal microchimerism led to local inflammation reactions (34). In contrast, Johnson
et al. could not find fetal microchimerism in scleroderma as an autoimmune disease (35), but they reported the presence of such a cell in non-autoimmune diseases (29). Immunostaining results showed the presence of EGFP-positive cells in the connective tissue infiltrated by leukocytes after caerulein induction and pregnancy. These cells were adipocyte-like and mesenchymal-like cells. Such cell could not be identified in the pancreas of the pregnant sham mice. The origin of FMCs is various; trophoblasts, leukocytes and mesenchymal stem cells have been suggested as the origin of microchimerism in the lung (13). Mesenchymal stem cells have been shown to play a critical role in immunomodulation (36) by the production of some cytokines (37). Fetal stem cells have been reported to modify the cytokines in the wound microenvironment of pregnant mice compared with non-pregnant ones (38). The presence of EGFP-positive mesenchymal-like cells may be involved in the reduction in the score of the inflammation process in pregnant pancreatitis-induced compared with virgin-pancreatitis mice and it may be due to the production of immunomodulatory cytokines.

The beneficial effects of the presence of microchimerism in various diseases were shown previously. Pregnancy has been also shown to prevent systemic sclerosis (39) and plays a role in scarless wound healing (38). The improvement of lupus nephritis was recorded in the patients with fetal microchimerism DNA (40); however, the effects were variable according to the disease stage and sex of the fetus (41). The adverse effects of fetal microchimerism were detected in some other diseases such as hypersensitivity pneumonitis (42). The data of the current study revealed an improvement in the scoring of pancreatitis in the animals experiencing pregnancy compared with virgin ones.

The limitation of this study was the inaccuracy of the procedure to find a very scant amount of DNA belonging to the embryo in pregnant sham animals. This study also could not find the natural niche of microchimeric cells in the mother’s pancreas. Another limitation of this study was the lack of characterization of the GFP-positive cells with mesenchymal cell phenotype.

**Conclusion**

Pregnancy was shown to have a beneficial impact on caerulein-induced pancreatitis. FMCs was shown to differentiate into several cell types including acinar cells in both pregnant sham and caerulein-induced pancreatitis animals and adipocyte and mesenchymal-like cells in pregnant caerulein-induced pancreatitis animals. It seems that the cell populations derived from FMCs depend on the health status of the pancreas. Although pregnancy did not treat pancreatitis completely, it led to improved scoring criterion.

**Acknowledgment**

The authors wish to thank the Vice Chancellery of Research Deputy of Shiraz University of Medical Sciences, Shiraz, Iran, for financial support by offering (grant no 7492) and also Nadimi for excellent technical support. This work was done by MJ Bagheri as a part of the requirements for an MS degree. The authors would like to thank the Center for Development of Clinical Research of Nemazee Hospital, Shiraz, Iran and Dr. Nasrin Shokrpour for editorial assistance.

**Conflicts of interest**

There are no conflicts of interest.

**Financial support**

The authors wish to thank the Vice Chancellery of Research Deputy of Shiraz University of Medical Sciences, Shiraz, Iran (grant no 7492).

**References**

1. Nelson JL. The otherness of self: microchimerism in health and disease. Trends Immunol 2012;33:421-427.
2. Gill RM, Lee TH, Utter GH, Reed WF, Wen L, Chafets D, et al. The TNF (308A) polymorphism is associated with microchimerism in transfused trauma patients. Blood 2008; 111: 3880-3883.
3. Boyon C, Collinet P, Boulanger L, Rubod C, Lucot JP, Vinatier D. Fetal microchimerism: benevolence or malevolence for the mother? Eur J Obstet Gynecol Reprod Biol 2011; 158:148-152.
4. Kiupin MA. Microchimerism: Sharing Genes in Illness and in Health. ISRN Nurs 2011; 2011: 893819.
5. Schnitzer M, Fisch P. A role for microchimerism in obesity and evolution? Med Hypotheses 2012; 78:528-532.
6. Fugazzola L, Cirello V, Beck-Peccoz P. Microchimerism and endocrine disorders. TJ Clin Endocrinol Metab 2012; 97:1452-1461.
7. Sunami R, Komuro M, Tagaya H, Hirata S. Migration of microchimeric fetal cells into maternal circulation before placenta formation. Chimerism 2010; 1: 66-68.
8. Dawe GS, Tan XW, Xiao ZC. Cell migration from baby to mother. Cell Adh Migr 2007; 1:19-27.
9. Klönsch, Drouin R. Fetal-maternal exchange of multipotent stem/progenitor cells: microchimerism in diagnosis and disease. Trends Mol Med 2009; 15:510-518.
10. Khosrotehrani K, Johnson KL, Cha DH, Salomon RN, Bianchi DW. Transfer of fetal cells with multilineage potential to maternal tissue. LAMA 2004; 292:75-80.
11. Lee ES, Bov-Gharlos G, Seppanen E, Khosrotehrani K, Fisk NM. Fetal stem cell microchimerism: natural-born healers or killers? Mol Hum Reprod 2010; 16:869-878.
12. Khosrotehrani K, Bianchi DW. Multi-lineage potential of fetal cells in maternal tissue: a legacy in reverse. J Cell Sci 2005; 118:1559-1563.
13. Pritchard S, Peter I, Johnson KL, Bianchi DW. The natural history of fetal cells in postpartum murine maternal lung and bone marrow: A two-stage phenomenon. Chimerism 2012; 3:59-64.
14. Fujiki Y, Tao K, Bianchi DW, Giel-Moloney M, Leiter AB, Johnson KL. Quantification of green fluorescent protein by in vivo imaging, PCR, and flow cytometry: comparison of transgenic strains and relevance for fetal cell microchimerism. Cytometry A 2008; 73:11-118.
15. Klönsch, Drouin R, Khosrotehrani K, Johnson KL, Lau J, Dupuy A, Cha DH, Bianchi DW. The influence of fetal loss on the presence of fetal cell microchimerism: a systematic review. Arthritis Rheum 2010; 62:3237-3241.
16. O’Donoghue K, Chan J, de la Fuente J, Kenea N, Sandison A, Anderson JR, et al. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. Lancet 2004; 364:179-182.
17. Wang Y, Iwatani H, Ito T, Horimoto N, Yamato M, Matsui I, et al. Fetal cells in mother rats contribute to the remodeling of liver and kidney after injury. Biochem Biophys Res Commun 2004; 325:961-967.
18. Bayes-Genis A, Bellosillo B, de la Calle O, Salido M, Roura S, Ristol FS, et al. Identification of male cardiomyocytes of extracardiac origin in the hearts of women with male progeny:
male fetal cell microchimerism of the heart. J Heart Lung Transplant 2005; 24:2179-2183.
19. Santos MA, O'Donoghue K, Wyatt-Ashmead J, Fisk NM. Fetal cells in the maternal appendix: a marker of inflammation or fetal tissue repair? Hum Reprod 2008; 23:2319-2325.
20. Zhang G, Zhao Y, Li XM, Kong J. Fetal cell microchimerism in the maternal mouse spinal cord. Neurosci Bull 2014; 30:81-89.
21. Nelson JL. Microchimerism and scleroderma. Curr Rheumatol Rep 1999; 1:15-21.
22. Lambert N. Microchimeric cells: guardians or actors of immunity in scleroderma? Rheumatology (Oxford) 2007; 46:382-383.
23. Ye Y, Berendine VZ, Hellmich C, Gillespie KM. Microchimerism: covert genetics? Int J Mol Epidemiol Gene 2010; 1:350-357.
24. VanZyl B, Gillespie KM. Microchimerism in type 1 diabetes. Curr Diab Rep 2009; 9:125-129.
25. Nguyen Huu S, Oster M, Avril MF, Mortier L, Richard MA, et al. Fetal microchimeric cells participate in tumour angiogenesis in melanomas occurring during pregnancy. Am J Pathol 2009; 174:630-637.
26. Johnson KL, Samura O, Nelson JL, McDonnell M d WM, Bianchi DW. Significant fetal cell microchimerism in a nontransfused woman with hepatitis C: Evidence of long-term survival and expansion. Hepatology 2002; 36:1295-1297.
27. Sunami R, Komuro M, Yuminamochi T, Hoshi K, Hirata S. Fetal cell microchimerism develops through the migration of fetus-derived cells to the maternal organs early after implantation. J Reprod Immunol 2010; 84:117-123.
28. Tan XW, Liao H, Sun L, Okabe M, Xiao ZC, Dawe GS. Fetal microchimerism in the maternal mouse brain: a novel population of fetal progenitor or stem cells able to cross the blood–brain barrier? Stem Cells 2005; 23:1443-1452.
29. Carvalho KM, Morais TC, de Melo TS, de Castro Brito GA, de Andrade GM, Rao VS, et al. The natural flavonoid quercetin ameliorates cerulein-induced acute pancreatitis in mice. Biol Pharm Bull 2010; 33:1534-1539.
30. Ratary MG, Murphy JA, Mcloughlin E, Smith D, Criddle D, Sutton R. Mechanisms of acinar cell injury in acute pancreatitis. Scand J Surg 2005; 94:89-96.
31. Lerch MM, Gorelick FS. Models of acute and chronic pancreatitis. Gastroenterology 2013; 144:1180-1193.
32. Warzecha Z, Sendur P, Ceranowicz P, Dembiński M, Gieszkowski J, Kuśnierz-Cabala B, et al. Protective Effect of Pretreatment with Acenocoumarol in Cerulein-Induced Acute Pancreatitis. Int J Mol Sci 2016; 17: E1709.
33. Welsch T, Endlich K, Giese T, Büchler MW, Schmidt J. Eps8 is increased in pancreatic cancer and required for dynamic actin-based cell protrusions and intercellular cytoskeletal organization. Cancer Let 2007; 255:205-218.
34. Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, et al. Microchimerism and HLA-compatible relationships of pregnancy in systemic sclerosis. The Lancet 1998; 351:559-562.
35. Johnson KL, Nelson JL, Furst DE, McSweeney PA, Roberts DJ, Zhen DK, et al. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum 2001; 44:1848-1854.
36. Ayatollahi M, Talaee-Khozani T, Razmkhah M. Growth suppression effect of human mesenchymal stem cells from bone marrow, adipose tissue, and Wharton's jelly of umbilical cord on PBMCs. Iran J Basic Med Sci 2016; 19:145-1453.
37. Johnson KL, Nelson JL, Furst DE, McSweeney PA, Roberts DJ, Zhen DK, et al. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum 2001; 44:1848-1854.
38. Ayatollahi M, Talaee-Khozani T, Razmkhah M. Growth suppression effect of human mesenchymal stem cells from bone marrow, adipose tissue, and Wharton's jelly of umbilical cord on PBMCs. Iran J Basic Med Sci 2016; 19:145-1453.
39. Artlett CM, Rasheed M, Russo-Stieglitz KE, Savoldi-Barbosa M, et al. Fetal microchimerism in kidney biopsies of lupus nephritis patients may be associated with a beneficial effect. Arthritis Res Ther 2015; 17:101.
40. Florim GM, Caldas HC, de Melo JC, Baptista MA, Fernandes IM, Savoldi-Barbosa M, et al. Fetal microchimerism in kidney biopsies of lupus nephritis patients may be associated with a beneficial effect. Arthritis Res Ther 2015; 17:101.
41. da Silva Florim GM, Caldas HC, Pavarino EC, Bertollo EM, Bertollo EM, Fernandes IM, Abdur-Filho M. Variables associated to fetal microchimerism in systemic lupus erythematosus patients. Clin Rheumatol 2016; 35:107-111.
42. Bustos ML, Hájar B, Ramo S, Estrada A, Arreola JL, Mendoza F, et al. Local and circulating microchimerism is associated with hypersensitivity pneumonitis. Am J Respir Crit Care Med 2007; 176:90-95.